ImmunityBio Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
ImmunityBio, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue14.750.620.240.930.61
Cost of Revenue0.000.000.000.000.00
Gross Profit14.750.620.240.930.61
Operating Expenses
Research & Development190.14226.67248.15191.60140.26
Selling, General & Administrative168.78135.32102.71126.7661.02
Operating Expenses358.93361.99350.86318.36201.28
Operating Income-344.18-361.36-350.62-317.42-200.67
Other Income/Expense
Interest Income2.401.132.710.842.44
Interest Expense131.66-129.2047.15-14.85-9.07
Other Income/Expense-69.46-84.44-5.864.810.02
Income
Income Before Tax-413.65-583.89-417.29-349.84-226.03
Income Tax Expense0.00-0.040.030.01-1.85
Net Income-413.56-583.20-416.57-346.79-221.85
Net Income - Continuous Operations-413.56-583.85-417.32-349.850.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-264.43-342.85-351.88-303.19-187.93
EBIT-188.12-361.36-370.14-317.42-200.67
Depreciation & Amortization17.5518.5118.2614.2412.74
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-1.00
Diluted EPS-1.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding697.31508.64399.90389.23377.07
Diluted Shares Outstanding700.44508.64399.90389.23377.07